A detailed history of Parallel Advisors, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 593 shares of ARWR stock, worth $14,866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
593
Previous 546 8.61%
Holding current value
$14,866
Previous $16,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$27.21 - $39.48 $1,278 - $1,855
47 Added 8.61%
593 $16,000
Q4 2023

Feb 09, 2024

BUY
$21.2 - $31.03 $11,575 - $16,942
546 New
546 $16,000
Q2 2023

May 20, 2024

SELL
$25.16 - $41.38 $930 - $1,531
-37 Reduced 68.52%
17 $0
Q2 2023

Aug 04, 2023

SELL
$25.16 - $41.38 $930 - $1,531
-37 Reduced 68.52%
17 $0
Q1 2023

May 20, 2024

SELL
$23.68 - $38.51 $12,763 - $20,756
-539 Reduced 90.89%
54 $1,000
Q1 2023

Apr 25, 2023

SELL
$23.68 - $38.51 $21,548 - $35,044
-910 Reduced 94.4%
54 $1,000
Q4 2022

Feb 03, 2023

BUY
$28.0 - $40.56 $4,620 - $6,692
165 Added 20.65%
964 $39,000
Q3 2022

Nov 10, 2022

BUY
$29.63 - $48.31 $533 - $869
18 Added 2.3%
799 $26,000
Q2 2022

Aug 01, 2022

BUY
$27.79 - $50.61 $2,084 - $3,795
75 Added 10.62%
781 $27,000
Q1 2022

Apr 28, 2022

SELL
$39.62 - $69.97 $4,477 - $7,906
-113 Reduced 13.8%
706 $32,000
Q4 2021

Jan 20, 2022

BUY
$58.09 - $82.51 $41,940 - $59,572
722 Added 744.33%
819 $54,000
Q3 2021

Nov 02, 2021

SELL
$58.38 - $84.96 $8,406 - $12,234
-144 Reduced 59.75%
97 $6,000
Q2 2021

Aug 06, 2021

BUY
$62.15 - $90.32 $4,536 - $6,593
73 Added 43.45%
241 $20,000
Q1 2021

Apr 23, 2021

SELL
$61.35 - $90.47 $27,239 - $40,168
-444 Reduced 72.55%
168 $11,000
Q4 2020

Feb 02, 2021

BUY
$43.82 - $85.37 $24,232 - $47,209
553 Added 937.29%
612 $47,000
Q2 2020

Jul 16, 2020

BUY
$26.12 - $43.27 $914 - $1,514
35 Added 145.83%
59 $2,000
Q1 2020

Apr 27, 2020

BUY
$20.56 - $63.12 $493 - $1,514
24 New
24 $0

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.65B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.